SCHEMBL4933022

SCHEMBL4933022

O=C(C=Cc1ccc(C(Cc2ccccc2)NC(=O)NC(=O)c2ccccc2)cc1)NO

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 11/20 0.52
HDAC1 Q13547 11/20 0.52
HDAC3 O15379 10/20 0.52
HDAC8 Q9BY41 10/20 0.52
HDAC4 P56524 9/20 0.52
HDAC6 Q9UBN7 9/20 0.52
HDAC7 Q8WUI4 8/20 0.52
HDAC10 Q969S8 8/20 0.52
HDAC11 Q96DB2 8/20 0.52
HDAC9 Q9UKV0 8/20 0.52
HDAC5 Q9UQL6 8/20 0.52
CCR3 P51677 1/20 0.44
NOS2 P35228 3/20 0.43
NOS3 P29474 2/20 0.43
NOS1 P29475 2/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4921889 0.90 HDAC1 (0.53) HDAC2HDAC1HDAC3HDAC8HDAC4
SCHEMBL4933486 0.89 HDAC2 (0.50) HDAC2HDAC1HDAC3HDAC8HDAC4
SCHEMBL4930697 0.88 HDAC1 (0.52) HDAC2HDAC1HDAC3HDAC8HDAC4
SCHEMBL4931294 0.87 HDAC1 (0.55) HDAC2HDAC1HDAC3HDAC8HDAC4
SCHEMBL4931762 0.87 HDAC1 (0.51) HDAC2HDAC1HDAC3HDAC8HDAC4
SCHEMBL4928501 0.86 HDAC1 (0.50) HDAC2HDAC1HDAC3HDAC8HDAC4
SCHEMBL4930143 0.86 HDAC1 (0.50) HDAC2HDAC1HDAC3HDAC8HDAC6
SCHEMBL4922709 0.85 HDAC2 (0.49) HDAC2HDAC1HDAC3HDAC8HDAC4
SCHEMBL4929990 0.85 HDAC1 (0.49) HDAC2HDAC1HDAC3HDAC8HDAC4
SCHEMBL4929939 0.85 HDAC1 (0.49) HDAC2HDAC1HDAC3HDAC8HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080070954-A1 Acylurea Connected And Sulfonylurea Connected Hydroxamates S*BIO PTE LTD. (SG) 2008-03-20 US claimed
EP-1685094-A4 ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES S BIO PTE LTD (SG) 2007-08-22 EP claimed
EP-1685094-A1 ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES S*Bio Pte Ltd (SG) 2006-08-02 EP claimed
WO-2005040101-A1 ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES S*BIO PTE LTD (SG) 2005-05-06 WO claimed
US-20080070954-A1 Acylurea Connected And Sulfonylurea Connected Hydroxamates S*BIO PTE LTD. (SG) 2008-03-20 US disclosed
EP-1685094-A4 ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES S BIO PTE LTD (SG) 2007-08-22 EP disclosed
EP-1685094-A1 ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES S*Bio Pte Ltd (SG) 2006-08-02 EP disclosed
WO-2005040101-A1 ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES S*BIO PTE LTD (SG) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070954-A1 Acylurea Connected And Sulfonylurea Connected Hydroxamates HDAC1, HDAC3, HDAC4 HDAC2 10/4885HDAC1 1/4885HDAC3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.